Ad hoc news

Ad hoc news 2018

24-07-2018

Elanix Biotechnologies AG resolves a capital increase of up to 10 percent equaling 2.1 Mio EUR with indirect subscription rights using the authorized capital

28-05-2018

Elanix Biotechnologies AG resolves a capital increase of up to 10 percent with the exclusion of subscription rights using the authorized capital

30-04-2018

Elanix Biotechnologies AG secures up to EUR 2.5 Million SEDA (Standby Equity Distribution Agreement) financing

20-02-2018

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

14-02-2018

Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million

Ad hoc news 2017

17-10-2017

Agreement in principle reached on the conditions for a non-cash capital increase against a contribution in kind for the progenitor bone cell bank from Inno 4 Cell AG

24-08-2017

Annual General Meeting resolves cash capital increase with preemptive rights at a subscription ratio of 4:1

22-08-2017

Elanix Biotechnologies AG starts due diligence to acquire a fetal progenitor bone cell line within a capital increase by way of contribution in kind

29-06-2017

Elanix Biotechnologies AG: Torsten Cejka, Chairman of the Supervisory Board resigns effective on the date of next General Meeting

13-07-2017

The Management and Supervisory Board will propose to the annual general meeting a capital increase against cash contributions up to 50% granting indirect subscription rights

30-01-2017

Elanix Biotechnologies AG initiates a cash capital increase from authorized capital of up to 1,133,200 new shares with indirect shareholder subscription rights

15-04-2017

Elanix Biotechnologies AG: Restatement gem. IAS 8 im Rahmen des Konzernabschlusses 2016 geplant/Vorläufige, ungeprüfte Konzernzahlen zum Geschäftsjahr 2016 und Ausblick

24-02-2017

Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million

13-01-2017

Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights

Ad hoc news 2016

20-06-2016

Elanix Biotechnologies AG: Vorstand Armin Schulz abberufen

11-08-2016

Elanix Biotechnologies AG: Kapitalerhöhung vollständig platziert

15-04-2016

Elanix Biotechnologies AG beschließt Kapitalerhöhung

29-07-2016

Elanix Biotechnologies AG beschließt Kapitalerhöhung gegen Bareinlagen aus genehmigtem Kapital

30-09-2016

ELANIX BIOTECHNOLOGIES AG subsidiary acquires 100% of equity of Repair-A SA

15-02-2016

Tomas Svoboda joins Management Board

04-01-2016

Reappointment of Supervisory Board

Ad hoc news 2015

24-09-2015

Porta Systems AG: Hauptversammlung schafft Voraussetzungen für Neuausrichtung als Biotechnologieunternehmen

09-12-2015

Restructuring to Biotech Company

Ad hoc news 2014

17-04-2014

Porta Systems AG wird zur ELANIX Biotech AG